On May 14, 2020 TG Therapeutics, Inc. (NASDAQ: TGTX), reported the schedule of upcoming data presentations at the 56thAmerican Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) annual meeting, to be held virtually May 29 – June 1, 2020 and the 25thEuropean Hematology Association (EHA) (Free EHA Whitepaper) annual congress, to be held virtually June 11 – 14, 2020 (Press release, TG Therapeutics, MAY 14, 2020, View Source [SID1234557996]). Details of the data presentations are included below.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer stated, "We are extremely pleased to present data from three combination trials at the upcoming June conferences, which we believe underscores the progress we have made in our combinatorial approach, as well as the potential utility of our lead drug candidates in oncology. We are particularly excited to share the final results from the GENUINE Phase 3 trial, evaluating ublituximab in high-risk CLL patients, which is the first randomized trial to demonstrate a PFS benefit with the addition of an anti-CD20 antibody to ibrutinib, compared to ibrutinib monotherapy. Additionally, it is encouraging to see long-term results from the combination of umbralisib and ibrutinib continue to show the potential versatility of umbralisib in combination regimens." Mr. Weiss continued, "Lastly, we look forward to presenting updated results from our proprietary triple combination of ublituximab, umbralisib, and our highly selective, BTK inhibitor, TG-1701, which to date has shown encouraging clinical activity at all dose levels evaluated."
Data to be presented at the ASCO (Free ASCO Whitepaper) meeting:
Presentation Title: Effect of adding ublituximab to ibrutinib on PFS, ORR, and MRD negativity in previously treated high-risk chronic lymphocytic leukemia: Final results of the GENUINE phase III study
Abstract Number: 7506
Available on Demand: Friday, May 29, 2020 at 8:00 AM ET
Session Title: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Lead Author: Jeff P. Sharman, MD, Willamette Valley Cancer Institute, US Oncology Research, Eugene, OR
The above abstract is now available via the ASCO (Free ASCO Whitepaper) meeting website at www.asco.org.
Data to be presented at the EHA (Free EHA Whitepaper) meeting:
Presentation Title: Long term results of a Phase I/Ib study of ibrutinib in combination with umbralisib in patients with relapsed/refractory CLL or MCL
Abstract Number: EP689
Available on Demand: Friday, June 12, 2020 at 8:30 CEST
Session Title: Chronic lymphocytic leukemia and related disorders – Clinical
Lead Author: Matthew Davids, MD, MMSc, Medical Oncology, Dana Farber Cancer Institute, Boston, MA
Presentation Title: Safety and activity of the once daily selective bruton tyrosine kinase (BTK) inhibitor TG-1701 in patients with chronic lymphocytic leukemia (CLL) and lymphoma
Abstract Number: EP705
Available on Demand: Friday, June 12, 2020 at 8:30 CEST
Session Title: Chronic lymphocytic leukemia and related disorders – Clinical
Lead Author: Chan Cheah, MD, Haematology, Linear Clinical Research, and Sir Charles Gardiner Hospital, Nedlands, Australia
The above abstracts are now available via the EHA (Free EHA Whitepaper) meeting website at www.ehaweb.org.
Following each presentation, the data presented will be available on the Publications page, located within the Pipeline section, of the Company’s website at www.tgtherapeutics.com/publications.cfm.